315 related articles for article (PubMed ID: 19679545)
21. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
22. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
23. The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK.
Ageberg M; Gullberg U; Lindmark A
Haematologica; 2006 Feb; 91(2):268-9. PubMed ID: 16461319
[TBL] [Abstract][Full Text] [Related]
24. Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
Wang DM; Liu L; Fan L; Zou ZJ; Zhang LN; Yang S; Li JY; Xu W
Cancer Biol Ther; 2012 Dec; 13(14):1522-8. PubMed ID: 23052131
[TBL] [Abstract][Full Text] [Related]
25. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
[TBL] [Abstract][Full Text] [Related]
26. Glutathione and Bcl-2 targeting facilitates elimination by chemoradiotherapy of human A375 melanoma xenografts overexpressing bcl-xl, bcl-2, and mcl-1.
Mena S; Rodriguez ML; Ortega A; Priego S; Obrador E; Asensi M; Petschen I; Cerdá M; Brown BD; Estrela JM
J Transl Med; 2012 Jan; 10():8. PubMed ID: 22233801
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.
Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; deBock CE; Thorne RF; Allen J; Hersey P; Zhang XD
Cancer Res; 2008 Aug; 68(16):6708-17. PubMed ID: 18701495
[TBL] [Abstract][Full Text] [Related]
28. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
[TBL] [Abstract][Full Text] [Related]
29. Bcl-2 family proteins and cytoskeleton changes involved in DM-1 cytotoxic effect on melanoma cells.
Faião-Flores F; Suarez JA; Soto-Cerrato V; Espona-Fiedler M; Pérez-Tomás R; Maria DA
Tumour Biol; 2013 Apr; 34(2):1235-43. PubMed ID: 23341182
[TBL] [Abstract][Full Text] [Related]
30. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
31. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
32. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
33. DEK Expression is controlled by E2F and deregulated in diverse tumor types.
Carro MS; Spiga FM; Quarto M; Di Ninni V; Volorio S; Alcalay M; Müller H
Cell Cycle; 2006 Jun; 5(11):1202-7. PubMed ID: 16721057
[TBL] [Abstract][Full Text] [Related]
34. The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C; Järvstråt L; Lennartsson A; Brattås PL; Nilsson B; Gullberg U
Mol Cancer; 2014 Sep; 13():215. PubMed ID: 25216995
[TBL] [Abstract][Full Text] [Related]
35. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
36. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
37. Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the up-regulation of NF-κB p65.
Liu K; Feng T; Liu J; Zhong M; Zhang S
Biosci Rep; 2012 Jun; 32(3):323-32. PubMed ID: 22390170
[TBL] [Abstract][Full Text] [Related]
38. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Hersey P
Mod Pathol; 2007 Apr; 20(4):416-26. PubMed ID: 17384650
[TBL] [Abstract][Full Text] [Related]
39. Proteomic analysis of apoptosis related proteins regulated by proto-oncogene protein DEK.
Kim DW; Chae JI; Kim JY; Pak JH; Koo DB; Bahk YY; Seo SB
J Cell Biochem; 2009 Apr; 106(6):1048-59. PubMed ID: 19229864
[TBL] [Abstract][Full Text] [Related]
40. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
